LEADER 04853nam 2200853Ia 450 001 9910958947303321 005 20251017110114.0 010 $a9786611767525 010 $a9780309185691 010 $a0309185696 010 $a9781281767523 010 $a1281767522 010 $a9780309118675 010 $a0309118670 035 $a(CKB)2550000000004405 035 $a(EBL)3378374 035 $a(SSID)ssj0000288925 035 $a(PQKBManifestationID)11220286 035 $a(PQKBTitleCode)TC0000288925 035 $a(PQKBWorkID)10383139 035 $a(PQKB)10130252 035 $a(MiAaPQ)EBC3378374 035 $a(Au-PeEL)EBL3378374 035 $a(CaPaEBR)ebr10237094 035 $a(CaONFJC)MIL176752 035 $a(OCoLC)923279005 035 $a(Perlego)4740388 035 $a(DNLM)1480731 035 $a(BIP)21074671 035 $a(EXLCZ)992550000000004405 100 $a20080521d2008 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 10$aAntivirals for pandemic influenza $eguidance on developing a distribution and dispensing program /$fCommittee on Implementation of Antiviral Medication Strategies for an Influenza Pandemic, Board on Population Health and Public Health Practice, Institute of Medicine of the National Academies 205 $a1st ed. 210 $aWashington, DC $cNational Academies Press$dc2008 215 $a1 online resource (x, 122 pages) 300 $aDescription based upon print version of record. 311 08$aPrint version: Institute of Medicine (U.S.). Committee on Implementation of Antiviral Medication Strategies for an Influenza Pandemic. Antivirals for pandemic influenza. Washington, DC : National Academies Press, ©2008 9780309118668 (DLC) 2008298577 (OCoLC)228498016 311 08$a9780309118668 311 08$a0309118662 320 $aIncludes bibliographical references. 327 $aIntroduction -- Antiviral effectiveness, safety, and supply -- Ethics, decision making, and communication -- Who should get antivirals and where? 330 $aPlanning for an influenza pandemic, whether it occurs in the near or distant future, will need to take into account many constantly evolving factors. The Institute of Medicine (IOM) Committee on Implementation of Antiviral Medication Strategies for an Influenza Pandemic was asked by the Department of Health and Human Services, (DHHS) to consider best practices and policies for providing antiviral treatment and prophylaxis during a pandemic event. The committee (TM)s report, entitled Antivirals for Pandemic Influenza: Guidance on Developing a Distribution and Dispensing Program, calls for a national and public process of creating an ethical framework for antiviral use within the context of uncertainty and scarcity. It is unclear whether antivirals will work against a pandemic strain as well as they work against seasonal influenza. Also, government stockpiles may not be sufficient for all possible uses in part because antivirals are costly and public health agencies must invest in other important activities, including other medical resources for pandemic influenza. Furthermore, the report identifies the lack of a science-based advisory body to guide decision making during the pandemic, including guidance on all dimensions of antiviral dispensing (for example, prioritization, drug safety, and antiviral resistance). The report also acknowledges the need for diverse methods and sites of dispensing, and discusses their advantages and disadvantages. 606 $aAntiviral agents$xEffectiveness 606 $aAntiviral agents 606 $aEpidemics$xPrevention 606 $aInfluenza$xPrevention 606 $aInfluenza, Human$xprevention & control$3(DNLM)D007251Q000517 606 $aAntiviral Agents$xsupply & distribution$3(DNLM)D000998Q000600 606 $aProgram Development$xmethods$3(DNLM)D016730Q000379 606 $aAntiviral Agents$xtherapeutic use$3(DNLM)D000998Q000627 606 $aDisease Outbreaks$xprevention & control$3(DNLM)D004196Q000517 615 0$aAntiviral agents$xEffectiveness. 615 0$aAntiviral agents. 615 0$aEpidemics$xPrevention. 615 0$aInfluenza$xPrevention. 615 12$aInfluenza, Human$xprevention & control. 615 12$aAntiviral Agents$xsupply & distribution. 615 12$aProgram Development$xmethods. 615 22$aAntiviral Agents$xtherapeutic use. 615 22$aDisease Outbreaks$xprevention & control. 676 $a614.518 712 02$aInstitute of Medicine (U.S.).$bBoard on Population Health and Public Health Practice. 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910958947303321 996 $aAntivirals for pandemic influenza$94365666 997 $aUNINA